Source-grounded facts extracted from HERON THERAPEUTICS, INC. /DE/'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HERON THERAPEUTICS, INC. /DE/ reported the three months ended March 31, 2026 results: revenue $34.7 million. Guidance reaffirmed.
“Reaffirms Guidance - Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF ® (+27%) and APONVIE ® (+50%) - Q1 2026 total net revenue of $34.7 million - Reached settlement with Baxter Healthcare Corporation in CINVANTI ® patent litigation - Reaffirmed 2026 full-year guidance of $173–$183 million net revenue; $10–$20 million”
HERON THERAPEUTICS, INC. /DE/: Filing of Certificate of Designation of Series A Convertible Preferred Stock (effective 2025-08-11).
“the Board authorized and the Company filed, on August 11, 2025, the Certificate of Designation of Rights, Preferences and Privileges (the “Certificate of Designation’) of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Convertible Preferred Stock”), with the Secretary of State of the State of Delaware.”
HERON THERAPEUTICS, INC. /DE/ incurred convertible notes of aggregate purchase price of $35.0 million with Rubric Capital Management LP at 5% per annum interest maturing 55 months.
“On August 8, 2025, the Company, entered into a Note Purchase Agreement (the “2031 Note Purchase Agreement”) with the purchasers from time to time party thereto (collectively, the “Purchasers”) and Rubric Capital Management LP, a Delaware limited partnership (“Rubric”), as agent for the Purchasers, pursuant to which the Company will issue and sell to the Purchasers convertible senior unsecured promissory notes for an aggregate purchase price of $35.0 million pursuant to exemptions from registration under Section 4(a)(2) under the Securities Act of 1933, as amended (the “Convertible Note Issuance”).”
HERON THERAPEUTICS, INC. /DE/ incurred credit facility of up to $150.0 million with Hercules Capital, Inc. at Prime (7.5% floor) plus 1.95% cash interest and 1.00% paid-in-kind interest maturing the earlier of (i) September 1, 2030 and (ii) to the extent that the Company issues convertible indebtedness, the date 180 days prior to the stated maturity the.
“institutions or entities from time to time parties thereto. The Second Amendment amends the Loan Agreement (a) to increase the aggregate principal amount of terms loans of up to $150.0 million plus accrued and unpaid paid-in-kind interest on the existing debt, with tranched availability as follows: $110.0 million plus accrued and unpaid paid-in-kind interest on the”
Mark Hensley was appointed as Chief Operating Officer at HERON THERAPEUTICS, INC. /DE/.
“On April 28, 2025, Heron Therapeutics, Inc. (the “ Company ”) announced that it appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025”
Michael Kaseta was appointed as Director at HERON THERAPEUTICS, INC. /DE/.
“On November 4, 2024, the Board of Directors (the "Board") of Heron Therapeutics, Inc. (the "Company") appointed Michael Kaseta to the Board to serve for a term expiring at the Company’s 2025 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.”
HERON THERAPEUTICS, INC. /DE/ reported three months ended March 31, 2024 results: revenue Net Product Sales of $34.7 million, EPS Net Loss Per Share $(0.02). Guidance reaffirmed.
“Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.”
Lisa Peraza departed as Chief Accounting Officer at HERON THERAPEUTICS, INC. /DE/.
“Ms. Peraza will continue to serve in her current position until her employment with the Company ends on the Effective Date.”
Ira Duarte changed role as principal accounting officer at HERON THERAPEUTICS, INC. /DE/.
“On March 18, 2024, Ira Duarte was designated as Heron Therapeutics, Inc.’s principal accounting officer, replacing Lisa Peraza, the Company’s current Chief Accounting Officer and principal accounting officer, effective March 29, 2024 (the “Effective Date”).”
HERON THERAPEUTICS, INC. /DE/ updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).
“On March 12, 2024, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023 (“Earnings Press Release”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.